Daily Ards Research Analysis
Three impactful ARDS studies span precision subphenotyping, mechanobiology of ventilation-induced injury, and pharmaco-epidemiology. A multicenter reanalysis shows inflammatory ARDS subphenotypes remain largely stable over 28 days; a mechanistic study implicates macrophage–epithelial gap junctions in exacerbating airway reopening injury; and a large cohort associates oral anticoagulant use with lower short-term mortality in ARDS.
Summary
Three impactful ARDS studies span precision subphenotyping, mechanobiology of ventilation-induced injury, and pharmaco-epidemiology. A multicenter reanalysis shows inflammatory ARDS subphenotypes remain largely stable over 28 days; a mechanistic study implicates macrophage–epithelial gap junctions in exacerbating airway reopening injury; and a large cohort associates oral anticoagulant use with lower short-term mortality in ARDS.
Research Themes
- Temporal stability of inflammatory ARDS subphenotypes
- Macrophage–epithelial gap junctions and airway reopening injury (VILI)
- Oral anticoagulation and short-term mortality in ARDS
Selected Articles
1. Temporal stability of inflammatory subphenotypes of acute respiratory distress syndrome: 28-day insights from the ICAR trial.
Reanalyzing the multicenter ICAR trial, two inflammatory ARDS subphenotypes were identified and remained largely stable over 28 days. The hyperinflammatory group had markedly higher mortality and organ failure and showed low probability of transitioning to the hypoinflammatory state.
Impact: Temporal stability strengthens the rationale for biomarker-based enrichment and precision therapies in ARDS. The probabilistic model offers a framework for monitoring trajectories and tailoring interventions.
Clinical Implications: Subphenotype monitoring could guide trial design (enrichment of hyperinflammatory patients) and inform response-adaptive strategies. It supports using biomarker panels for prognostication and potentially tailoring immunomodulatory therapies.
Key Findings
- Two ARDS subphenotypes (hypoinflammatory 83%, hyperinflammatory 17%) were identified at baseline.
- Hyperinflammatory subphenotype had higher 28-day mortality (52% vs 25%) and fewer ventilator-free days.
- Markov modeling showed few transitions: hypoinflammatory patients remained hypoinflammatory (70%) or were extubated (17%); hyperinflammatory patients remained hyperinflammatory (52%) or died (23%).
Methodological Strengths
- Prospective multicenter dataset from a randomized trial with serial biomarker measurements
- Robust unsupervised clustering and Bayesian discrete-time Markov modeling of state transitions
Limitations
- Secondary analysis limited to COVID-19-related ARDS; generalizability to non-COVID ARDS uncertain
- Modest sample size (n=146) and reliance on selected plasma biomarkers
Future Directions: Prospective, biomarker-stratified interventional trials targeting hyperinflammatory ARDS; external validation across non-COVID ARDS and diverse ICUs; assessment of treatment effect heterogeneity by subphenotype.
BACKGROUND: International guidelines have emphasized the necessity of evaluating the temporal stability of acute respiratory distress syndrome (ARDS) subphenotypes. This study aimed to assess the temporal stability of subphenotypes of ARDS over 28 days. METHODS: A reanalysis of a randomized trial was conducted, including patients with COVID-19-related moderate-to-severe ARDS across 43 centers. A K-means clustering was conducted to identify subphenotypes at 7-day intervals from inclusion to day 28. A Bayesian discrete-time Markov model was constructed to assess the temporal stability of subphenotypes. RESULTS: Two subphenotypes were identified among 146 patients. At inclusion, 121 (83%) patients were in the hypoinflammatory subphenotype and 25 (17%) in the hyperinflammatory subphenotype. The hyperinflammatory subphenotype was associated with higher rates of organ failure, higher plasma levels of cytokines, chemokines, adhesion molecules, and proangiogenic factors, and lower endothelial stability than the hypoinflammatory subphenotype. The hyperinflammatory subphenotype was associated with higher 28-day mortality (13/25, 52% vs. 30/121, 25%, p = 0.001) and fewer ventilatory-free-days through day 28 (p < 0.01) than the hypoinflammatory subphenotype. In the Bayesian Markov model, over 7-day intervals, patients in the hypoinflammatory subphenotype had a higher probability of remaining hypoinflammatory (70%) or being extubated (17%) than of progressing to the hyperinflammatory subphenotype (7%). Inversely, patients in the hyperinflammatory subphenotype had a higher probability of remaining in the hyperinflammatory subphenotype (52%) or dying (23%) than of transitioning to the hypoinflammatory subphenotype (20%) or being extubated (5%). CONCLUSIONS: Inflammatory subphenotypes were stable in COVID-19-related ARDS, with few transitions over 28 days. Monitoring these subphenotypes could be valuable for assessing patient trajectories and treatment responses.
2. Macrophage-Epithelial Interactions Modulate Epithelial Cell Injury During Airway Reopening.
In vitro airway reopening models showed that coculturing lung epithelial cells with macrophages increases membrane rupture and cell death, independent of soluble mediators. Blocking macrophage–epithelial gap junctions reduced injury, and biomechanical profiling implicated decreased stiffness and increased elasticity as mechanisms of macrophage-driven damage.
Impact: Identifying gap junction-mediated macrophage–epithelial crosstalk as a driver of atelectrauma provides a mechanistic target to mitigate ventilation-induced lung injury in ARDS.
Clinical Implications: While preclinical, these data suggest that modulating macrophage–epithelial communication (e.g., gap junction inhibitors) or biomechanical properties could reduce airway reopening injury during mechanical ventilation.
Key Findings
- Macrophage–epithelial coculture significantly increased epithelial membrane rupture and death during airway reopening.
- Injury augmentation was not due to soluble macrophage factors; inhibiting gap junctions reduced injury.
- Coculture altered epithelial mechanics (lower aspect ratio, lower elastic modulus, lower power-law exponent), implicating reduced stiffness/increased elasticity in injury exacerbation.
Methodological Strengths
- Use of both primary human alveolar macrophages and monocyte-derived macrophages with epithelial coculture
- Biomechanically relevant in vitro airway reopening model with quantitative morphological and viscoelastic measurements
Limitations
- In vitro design without in vivo validation limits generalizability
- Specific molecular gap junction components and signaling pathways were not fully delineated
Future Directions: Validate findings in animal models of ventilation-induced lung injury and test pharmacologic or genetic modulation of gap junctions; integrate single-cell profiling to map intercellular signaling during airway reopening.
During the acute respiratory distress syndrome (ARDS), bacterial/viral infections, including COVID-19, lead to significant pulmonary edema and severe hypoxia. Although ARDS patients often require mechanical ventilation (MV), the biophysical forces generated during MV are known to exacerbate lung injury resulting in ventilation-induced lung injury (VILI). During VILI, the complex biomechanical forces generated during the reopening of fluid-occluded airway/alveoli (atelectrauma) cause plasma membrane rupture and epithelial cell death. However, it is not known how the interaction of immune cells, including alveolar macrophages, with epithelial cells alters the degree of atelectrauma. We used in vitro modeling techniques to investigate how coculture of both monocyte derived macrophages and primary human alveolar macrophages with lung epithelial cells alters the degree of cell injury during airway reopening. Coculture of epithelial cells with macrophages led to a significant increase in epithelial cell death/plasma membrane rupture during airway reopening, and this increased injury was not due to soluble factors secreted by macrophages. Inhibiting macrophage-epithelial gap junction interactions decreased epithelial cell injury during airway reopening. Morphological and cell biomechanical measurements indicate that epithelial cells in coculture with macrophages have a lower height-to-width aspect ratio, a lower instantaneous elastic modulus, and a lower power-law exponent. Since lower aspect ratios have been associated with reduced atelectrauma, our data indicate that the reduced stiffness (lower elastic modulus) and increased elasticity (lower power-law exponent) are the biomechanical mechanism by which macrophages exacerbate epithelial cell injury during airway reopening.
3. Roles of oral anticoagulant use on the risk of 28-day mortality and in-hospital mortality in patients with acute respiratory distress syndrome.
In a large retrospective cohort with propensity score matching, oral anticoagulant use in ARDS was associated with lower 28-day (HR 0.32) and in-hospital mortality (HR 0.27). No mortality difference was detected between warfarin and direct oral anticoagulants.
Impact: Findings suggest a potentially modifiable pharmacologic exposure associated with improved short-term outcomes in ARDS, motivating mechanistic work and prospective trials.
Clinical Implications: These hypothesis-generating results do not justify routine initiation of anticoagulation solely for ARDS, but support careful continuation/individualization in patients already on oral anticoagulants and the design of RCTs to test efficacy and safety.
Key Findings
- Oral anticoagulant use was associated with reduced 28-day mortality in ARDS (HR 0.32, 95% CI 0.24–0.44).
- Oral anticoagulant use was associated with reduced in-hospital mortality (HR 0.27, 95% CI 0.20–0.37).
- No significant mortality difference between warfarin and direct oral anticoagulants was observed.
Methodological Strengths
- Use of multivariable Cox regression and propensity score matching to address confounding
- Subgroup analyses by ARDS severity and major comorbidities
Limitations
- Retrospective observational design with potential residual confounding and confounding by indication
- Exposure misclassification and heterogeneity in anticoagulant dosing/indications cannot be excluded
Future Directions: Conduct randomized controlled trials of anticoagulation strategies in ARDS with careful bleeding risk assessment; mechanistic studies of thromboinflammation and microthrombosis in ARDS.
AIM: This study was to investigate the association between oral anticoagulant use and 28-day mortality and in-hospital mortality in patients with acute respiratory distress syndrome (ARDS). METHODS: A total of 1754 ARDS patients were identified in database from 2008 to 2022 in this cohort study. Univariable and multivariable cox regression models were applied to assess the associations of oral anticoagulant use with the risk of 28-day mortality and in-hospital mortality. Propensity score matching (PSM) was performed in ARDS patients according to whether they were taking oral anticoagulants or not to control potential bias. Subgroup analysis was performed according to severity of ARDS (mild, moderate, and severe), and comorbidities (atrial fibrillation, sepsis, and AKI). Hazards ratio (HR) and respective confidence interval (CI) were presented. RESULTS: In total, 7758 patients not receiving oral anticoagulant and 905 patients receiving oral anticoagulant. The reduced risk of 28-day mortality in ARDS patients was identified in those undergoing oral anticoagulant use (HR = 0.32, 95%CI: 0.24-0.44). Oral anticoagulant use was associated with reduced risk of in-hospital mortality (HR = 0.27, 95%CI: 0.20-0.37). After adjusting for the respective confounding factors, the associations of Warfarin with decreased risk of 28-day and in-hospital mortality were not significant ( CONCLUSION: Oral anticoagulant was related to decreased risk of 28-day/in-hospital mortality in patients with ARDS. Warfarin and novel oral anticoagulants showed no significant difference on 28-day/in-hospital mortality in patients with ARDS.